Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions

被引:55
作者
Zhao, Yong-Xing [1 ]
Hua, Hai-Ying [2 ]
Chang, Min [1 ]
Liu, Wei-Jing [1 ]
Zhao, Yang [1 ]
Liu, Hong-Min [1 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Henan Province, Peoples R China
[2] Zhengzhou Univ, Acad Med & Pharmaceut Sci, Zhengzhou 450052, Henan Province, Peoples R China
关键词
Hydroxycamptothecin; Nanosuspensions; High-pressure homogenization; Precipitation; Cytotoxicity; POORLY SOLUBLE DRUGS; TOPOISOMERASE-I; CAMPTOTHECIN ANALOGS; BIOLOGICAL-ACTIVITY; OVARIAN-CARCINOMA; SERUM-ALBUMIN; DELIVERY; NANOPARTICLES; TECHNOLOGY; 10-HYDROXYCAMPTOTHECIN;
D O I
10.1016/j.ijpharm.2010.03.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hydroxycamptothecin is a promising anticancer agent that possesses the ability to inhibit the growth of a wide range of human tumors. Owing to its poor solubility and instability, the pharmaceutical development and clinical utilization of hydroxycamptothecin have been limited. In the present study, a novel precipitation-combined high-pressure homogenization (PCH) technique was used to prepare hydroxycamptothecin nanosuspensions. Based on the homogenization pressure and number of cycles, the process with 10 cycles at 18,000 psi of homogenization pressure was found to be the most efficient method to achieve consistent particle size reduction. It was used to prepare nanosuspensions for characterization and evaluation of the formulation performance. Lyophilization of hydroxycamptothecin nanosuspensions, the shape and crystal form of the drug, and antiproliferative activity were also studied. The mean particle size (z-ave) of the reconstituted freeze-dried powder was small and uniform. The freeze-dried powder might be a good choice for intravenously administrating poorly soluble hydroxycamptothecin, which proved to have higher cytotoxicity against the cancer cells than hydroxycamptothecin injections (p <0.001). Overall, these studies have demonstrated that the PCH technique can be used successfully to prepare hydroxycamptothecin nanosuspensions. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:64 / 71
页数:8
相关论文
共 37 条
  • [1] PREFERENTIAL BINDING OF THE CARBOXYLATE FORM OF CAMPTOTHECIN BY HUMAN SERUM-ALBUMIN
    BURKE, TG
    MI, ZH
    [J]. ANALYTICAL BIOCHEMISTRY, 1993, 212 (01) : 285 - 287
  • [2] Advances in lipid nanodispersions for parenteral drug delivery and targeting
    Constantinides, Panaylotis P.
    Chaubal, Mahesh V.
    Shorr, Robert
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (06) : 757 - 767
  • [3] Subcellular localization of the camptothecin analogues, topotecan and gimatecan
    Croce, AC
    Bottiroli, G
    Supino, R
    Favini, E
    Zuco, V
    Zunino, F
    [J]. BIOCHEMICAL PHARMACOLOGY, 2004, 67 (06) : 1035 - 1045
  • [4] Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma
    Han, JY
    Lee, DH
    Lee, SY
    Park, CG
    Kim, HY
    Lee, HG
    Lee, JJ
    Kim, HT
    Lee, JS
    [J]. CANCER, 2005, 104 (12) : 2759 - 2765
  • [5] MODIFICATION OF THE HYDROXY LACTONE RING OF CAMPTOTHECIN - INHIBITION OF MAMMALIAN TOPOISOMERASE-I AND BIOLOGICAL-ACTIVITY
    HERTZBERG, RP
    CARANFA, MJ
    HOLDEN, KG
    JAKAS, DR
    GALLAGHER, G
    MATTERN, MR
    MONG, SM
    BARTUS, JO
    JOHNSON, RK
    KINGSBURY, WD
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (03) : 715 - 720
  • [6] HSIANG YH, 1985, J BIOL CHEM, V260, P4873
  • [7] Cross-flow microfiltration of aggregated submicron particles
    Hwang, KJ
    Liu, HC
    [J]. JOURNAL OF MEMBRANE SCIENCE, 2002, 201 (1-2) : 137 - 148
  • [8] Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
    Keck, CM
    Müller, RH
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 62 (01) : 3 - 16
  • [9] Kipp JE., 2003, United States patent, Patent No. [6,607,784, 6607784, US6,607,784]
  • [10] Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs
    Kocbek, P
    Baumgartner, S
    Kristl, J
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 312 (1-2) : 179 - 186